Leukemia Therapy

Imatinib exacerbates idarubicin-induced hematopoietic toxicity

Published in Blood Weekly, April 24th, 2003

Imantinib exacerbates idarubicin-induced hematopoietic toxicity in leukemia patients.

Stem cell factor (SCF) "is a potent pro-proliferative cytokine crucial for hematopoiesis, which binds to c-kit and activates its tyrosine kinase activity," according to researchers in Italy. "Inactivating mutations of either SCF or c-kit have been described in mice and lead to increased sensitivity to treatment with ionizing radiation."

"Imatinib is a tyrosine kinase inhibitor with high affinity for c-Abl, PDGFR and c-kit," explained H. Ruchatz and colleagues at the National Cancer Institute, who "investigated the effect of concomitant administration of imatinib...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry